tetano
Editor, Senior Moderator
Inflamm Bowel Dis
. 2024 Oct 16:izae225.
doi: 10.1093/ibd/izae225. Online ahead of print. Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
Arthur J Kastl[SUP] 1 [/SUP], Erica J Brenner[SUP] 2 [/SUP], Kimberly N Weaver[SUP] 3 [/SUP], Xian Zhang[SUP] 2 [/SUP], Jennifer A Strople[SUP] 4 [/SUP], Jeremy Adler[SUP] 5 [/SUP], Marla C Dubinsky[SUP] 6 [/SUP], Athos Bousvaros[SUP] 7 [/SUP], Runa Watkins[SUP] 8 [/SUP], Xiangfeng Dai[SUP] 9 [/SUP], Wenli Chen[SUP] 9 [/SUP], Raymond K Cross[SUP] 10 [/SUP], Peter D R Higgins[SUP] 11 [/SUP], Ryan C Ungaro[SUP] 12 [/SUP], Meenakshi Bewtra[SUP] 13 [/SUP], Emanuelle A Bellaguarda[SUP] 14 [/SUP], Francis A Farraye[SUP] 15 [/SUP], Kelly Y Chun[SUP] 16 [/SUP], Michael Zikry[SUP] 16 [/SUP], Monique Bastidas[SUP] 16 [/SUP], Ann M Firestine[SUP] 17 [/SUP], Riley G Craig[SUP] 17 [/SUP], Margie E Boccieri[SUP] 2 [/SUP], Millie D Long[SUP] 18 [/SUP], Michael D Kappelman[SUP] 2 [/SUP]
Affiliations
Background: Children with inflammatory bowel disease (IBD) may have diminished serologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and increased risk for subsequent severe coronavirus disease 2019 (COVID-19) infection. We sought to describe outcomes among those who developed SARS-CoV-2 infection following vaccination, characterize SARS-CoV-2 antibodies 1 year post-vaccination, and identify factors associated with durable serologic response.
Methods: We recruited children with IBD who received ≥2 doses of SARS-CoV-2 vaccine and prospectively collected data on (1) demographics, IBD characteristics, and therapy and (2) SARS-CoV-2 vaccination, testing, and infection symptoms. Serum was obtained for measurement of anti-receptor-binding domain IgG antibodies following a 2-part immunization at 12 and 52 weeks.
Results: We enrolled 298 participants (mean age 11.9 ± 3.82, 50% female, 67% Crohn's disease). Symptomatic COVID-19 infection after vaccination occurred in half of the participants, although only 2 (1%) required hospitalization. Anti-tumor necrosis factor alpha (TNF-α) was associated with higher likelihood of symptomatic COVID-19 infection, with an adjusted hazard ratio of 2.7 (95% CI, 1.5-5.0; P = .001). Nearly all participants (99%) had detectable antibody at Week 52. Children aged 1-5 years had lower 52-week antibody level compared to older children (P = .04), as did those on anti-TNF-α therapy (P = .007) and those who received only 2 vaccine doses prior to Week 52 (P < .001).
Conclusions: SARS-CoV-2 vaccination provides lasting serologic response and protection against severe COVID-19 for most children with IBD, despite the use of lower vaccine doses in younger children and wide-ranging classes of immunosuppressive therapies.
Keywords: COVID-19; Crohn’s disease; humoral immune response; ulcerative colitis; vaccination.
. 2024 Oct 16:izae225.
doi: 10.1093/ibd/izae225. Online ahead of print. Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease
Arthur J Kastl[SUP] 1 [/SUP], Erica J Brenner[SUP] 2 [/SUP], Kimberly N Weaver[SUP] 3 [/SUP], Xian Zhang[SUP] 2 [/SUP], Jennifer A Strople[SUP] 4 [/SUP], Jeremy Adler[SUP] 5 [/SUP], Marla C Dubinsky[SUP] 6 [/SUP], Athos Bousvaros[SUP] 7 [/SUP], Runa Watkins[SUP] 8 [/SUP], Xiangfeng Dai[SUP] 9 [/SUP], Wenli Chen[SUP] 9 [/SUP], Raymond K Cross[SUP] 10 [/SUP], Peter D R Higgins[SUP] 11 [/SUP], Ryan C Ungaro[SUP] 12 [/SUP], Meenakshi Bewtra[SUP] 13 [/SUP], Emanuelle A Bellaguarda[SUP] 14 [/SUP], Francis A Farraye[SUP] 15 [/SUP], Kelly Y Chun[SUP] 16 [/SUP], Michael Zikry[SUP] 16 [/SUP], Monique Bastidas[SUP] 16 [/SUP], Ann M Firestine[SUP] 17 [/SUP], Riley G Craig[SUP] 17 [/SUP], Margie E Boccieri[SUP] 2 [/SUP], Millie D Long[SUP] 18 [/SUP], Michael D Kappelman[SUP] 2 [/SUP]
Affiliations
- PMID: 39412147
- DOI: 10.1093/ibd/izae225
Background: Children with inflammatory bowel disease (IBD) may have diminished serologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and increased risk for subsequent severe coronavirus disease 2019 (COVID-19) infection. We sought to describe outcomes among those who developed SARS-CoV-2 infection following vaccination, characterize SARS-CoV-2 antibodies 1 year post-vaccination, and identify factors associated with durable serologic response.
Methods: We recruited children with IBD who received ≥2 doses of SARS-CoV-2 vaccine and prospectively collected data on (1) demographics, IBD characteristics, and therapy and (2) SARS-CoV-2 vaccination, testing, and infection symptoms. Serum was obtained for measurement of anti-receptor-binding domain IgG antibodies following a 2-part immunization at 12 and 52 weeks.
Results: We enrolled 298 participants (mean age 11.9 ± 3.82, 50% female, 67% Crohn's disease). Symptomatic COVID-19 infection after vaccination occurred in half of the participants, although only 2 (1%) required hospitalization. Anti-tumor necrosis factor alpha (TNF-α) was associated with higher likelihood of symptomatic COVID-19 infection, with an adjusted hazard ratio of 2.7 (95% CI, 1.5-5.0; P = .001). Nearly all participants (99%) had detectable antibody at Week 52. Children aged 1-5 years had lower 52-week antibody level compared to older children (P = .04), as did those on anti-TNF-α therapy (P = .007) and those who received only 2 vaccine doses prior to Week 52 (P < .001).
Conclusions: SARS-CoV-2 vaccination provides lasting serologic response and protection against severe COVID-19 for most children with IBD, despite the use of lower vaccine doses in younger children and wide-ranging classes of immunosuppressive therapies.
Keywords: COVID-19; Crohn’s disease; humoral immune response; ulcerative colitis; vaccination.